HYLNHyliion Holdings Corp.
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- −$0.06Beat
- vs −$0.08 expected on Nov 10
- Price
- $2.76
- −0.90% today · $1.35B cap
Past and upcoming reports
1
| Nov 10, 2026 | Sep 30, 2026 | After the market closes | −$0.08 | Beat−$0.06 |
After the report
Nov 10, 2026 report
HYLN beat EPS estimates, but the 7.36% post-report decline signals unresolved profitability concerns
Hyliion reported September-quarter EPS of -$0.06 versus -$0.08 estimated, while shares fell to $2.77 on 3.07 million shares. revenue-guidance follow-through remains the key forward test.
Reported against expected
Reported EPS was -$0.06 for the quarter ended September 30, 2026, beating the -$0.08 estimate by $0.02, or 25%.
Guidance
RaisedManagement reportedly raised revenue guidance. the payload provides no numeric guidance target or margin outlook.
How the stock reacted
On November 11, shares fell $0.22, or 7.36%, from $2.99 to $2.77, with volume of 3.07 million. the reaction-window fields are unavailable.
What changed
EPS improved to -$0.06 from the -$0.08 estimate, while management raised revenue guidance.
What the price now assumes
The 7.36% decline on 3.07 million shares prices in continued losses despite the EPS beat and guidance raise.
What it means for the business
Maintain a mixed bias. upgrade only if revenue guidance converts into improving operating losses over the next 30-90 days.
The next one to three months, as we saw it then
Better case33%
Revenue-guidance follow-through could support the growth thesis if commercial expansion begins narrowing the operating deficit.
Base case33%
Shares remain volatile as revenue growth offsets a still-unproven path to profitability and the stock trades below its 20-day and 50-day averages.
Worse case33%
The guidance raise fails to offset cash-consumption concerns if revenue growth continues without meaningful loss reduction.
If you hold it
Hold only if revenue guidance remains intact and operating losses improve. trim if guidance is cut or the stock breaks below the $2.4545 200-day SMA.
If you are watching
Enter only after revenue-guidance follow-through coincides with improving operating losses. no trade while the stock remains below the $3.1752 20-day EMA without new fundamental confirmation.
Scenario odds are a judgement, not measured.